Investor Presentaiton
Performance: 2022 results and total to adjusted reconciliation
Turnover Operating
(£bn) profit (£bn)
2022 EPS
(pence)
2021
EPS
(pence)
Key dynamics
371.4
109.6
Total results - Total
Profit from discontinued
operations
(260.6)
(26.7)
Total results - Continuing
29.3
6.4
110.8
82.9
operations
Intangible amortisation
0.7
14.6
15.2
Intangible impairment
0.3
5.8
6.6
Major restructuring
0.3
5.9
8.7
Profit from discontinued operations
⑦Gain on demerger (fair value less book value)
⑰ Gain on retained stake on demerger (fair value less book value)
Transaction related
✓ ViiV contingent consideration liability movements (majority FX¹)
Divestments, significant legal and other
↑ Upfront income from the settlement with Gilead
↑ Fair value mark to market gain on the retained stake in Haleon
Transaction related
1.8
34.1
18.1
Divestments, significant
(1.4)
(31.5)
(21.2)
legal and other
Turnover: £29.3bn², 19% at AER, +13% at CER (ex-pandemic³ +10% CER)
Adj. OP4: £8.2bn², +26% at AER, +14% at CER (ex-pandemic³ +17% CER)
Adj. EPS: 139.7p², +27% at AER, +15% at CER (ex-pandemic³ +18% CER)
Adjusted results
29.3
8.2
139.7
110.3
Table may not sum due to rounding. See page 18 of GSK's fourth quarter 2022 earnings release for a full reconciliation.
1. Foreign exchange 2. Continuing results represents performance excluding discontinued operations 3. excluding COVID-19 solutions 4. Operating profit
GSK
21View entire presentation